UC-514321 manufacturers
- UC-514321
-
- $68.00
-
2026-04-20
- CAS:299420-83-0
- Purity: 98.50%
- Supply Ability: 10g
- UC-514321
-
- $68.00
-
2026-04-20
- CAS:299420-83-0
- Purity: 98.50%
- Supply Ability: 10g
|
| | UC-514321 Basic information |
| Product Name: | UC-514321 | | Synonyms: | UC-514321;1,3-Benzodioxol-5-ol, 6-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-4-morpholinylmethyl]-;AML,myeloid,low,toxicity,UC 514321,acute,leukemia,inhibit,UC-514321,Apoptosis,Inhibitor,UC514321,STAT;UC-514321, 10 mM in DMSO;6-((3,5-Di-tert-butyl-4-hydroxyphenyl)(morpholino)methyl)benzo[d][1,3]dioxol-5-ol | | CAS: | 299420-83-0 | | MF: | C26H35NO5 | | MW: | 441.56 | | EINECS: | | | Product Categories: | | | Mol File: | 299420-83-0.mol |  |
| | UC-514321 Chemical Properties |
| Boiling point | 514.5±50.0 °C(Predicted) | | density | 1.186±0.06 g/cm3(Predicted) | | pka | 9.80±0.20(Predicted) | | form | Solid | | color | White to off-white |
| | UC-514321 Usage And Synthesis |
| Uses | UC-514321, a structural analog of NSC370284 with higher activity, directly targets STAT3/5 and represses TET1 expression, but not TET2 or TET3. UC-514321 has the potential to treat acute myeloid leukemia (AML) both in vitro and in vivo, with low toxicity[1]. | | in vivo | UC-514321 (2.5 mg/kg, ip, once per day, for 10 days) exhibits more potent anti-tumor activity than NSC370284 in AML mice models[1]. | Animal Model: | MLL-AF9-AML mice and AE9a-AML model[1]. | | Dosage: | 2.5 mg/kg. | | Administration: | IP., once per day, for 10 days. | | Result: | Showed an improved therapeutic effect in AML mouse models in vivo.
Prolonged the median survival over three fold.
|
| | IC 50 | STAT3; STAT5; TET1 | | References | [1] Jiang X, et al. Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. Nat Commun. 2017 Dec 13;8(1):2099. DOI:10.1038/s41467-017-02290-w |
| | UC-514321 Preparation Products And Raw materials |
|